Moderna (NASDAQ:MRNA) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Moderna (NASDAQ:MRNA) in a report released on Wednesday morning. The brokerage issued an equal weight rating and a $25.00 price target on the stock.

Other analysts have also recently issued research reports about the company. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a research report on Monday, January 19th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research report on Monday, January 5th. Berenberg Bank set a $28.00 target price on Moderna in a research note on Monday, November 17th. BMO Capital Markets upgraded Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus target price of $28.77.

Moderna Price Performance

Moderna stock opened at $44.07 on Wednesday. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $55.20. The firm’s 50 day simple moving average is $33.96 and its 200-day simple moving average is $29.25. The company has a market cap of $17.22 billion, a P/E ratio of -5.46 and a beta of 1.17.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same quarter in the prior year, the firm earned $0.03 EPS. The firm’s quarterly revenue was down 45.4% on a year-over-year basis. On average, analysts expect that Moderna will post -9.61 EPS for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. Norges Bank bought a new stake in Moderna in the second quarter worth $94,910,000. Federated Hermes Inc. lifted its position in shares of Moderna by 364.5% in the second quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock worth $79,163,000 after buying an additional 2,251,497 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Moderna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after acquiring an additional 1,420,690 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Moderna by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after acquiring an additional 1,312,192 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Moderna by 20.7% during the 2nd quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock valued at $195,917,000 after acquiring an additional 1,217,408 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna announced a global commercialization collaboration with Recordati for its investigational propionic acidemia therapy mRNA?3927, under which Moderna keeps development control and can receive up to $160M in upfront/near?term milestones plus royalties — a near?term cash and de?risking event for a rare?disease program. RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA
• Positive Sentiment: Moderna named Dr. David Berman as Chief Development Officer effective March 2, 2026 — a senior hire that could bolster investor confidence in clinical execution and pipeline progression. Dr. David Berman to Join Moderna as Chief Development Officer
• Neutral Sentiment: Barclays has initiated coverage of Moderna, which can influence flows depending on the firm’s rating and target but is not an immediate operational development. Barclays Initiates Coverage on Moderna
• Neutral Sentiment: Public commentary (e.g., Jim Cramer) remains mixed — high-profile media comments can sway retail interest but don’t change fundamentals. Jim Cramer on Moderna: “We Have to Wait and See”
• Negative Sentiment: Chief Medical Officer Jacqueline Miller, a leader on Spikevax and key development executive, will step down effective March 2 — leadership turnover in clinical oversight raises near?term execution uncertainty. Moderna CMO Jacqueline Miller to step down
• Negative Sentiment: Reports that Moderna is rethinking late?stage vaccine funding and investor risk allocation have raised concerns about how the company will finance and prioritize its pipeline, compounding worries from prior quarters of falling COVID vaccine revenue and negative EPS. Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.